Infection with a molecularly cloned SIVsm virus elicits high titer homologous neutralizing antibodies with heterologous neutralizing activity

Journal of Medical Primatology

Volumn 34, Issue 5-6 SPEC. ISS., 2005, Pages 253-261

  Mahalanabis, M ^a,b   Hirsch, V M ^c   Haigwood, Nancy L ^a,b  

^a SEATTLE BIOMEDICAL RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

Broad neutralization; N linked glycosylation; Simian immunodeficiency virus

Indexed keywords

GLYCOPROTEIN GP 120; NEUTRALIZING ANTIBODY;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY TITER; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DNA ISOLATION; FOLLOW UP; GENE SEQUENCE; GLYCOSYLATION; MACACA; MOLECULAR CLONING; MONKEY DISEASE; NONHUMAN; PHYLOGENY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SEQUENCE ALIGNMENT; SEQUENCE ANALYSIS; SEQUENCE HOMOLOGY; SIMIAN IMMUNODEFICIENCY VIRUS; SPECIES DIFFERENCE; VIRUS INFECTION; VIRUS NEUTRALIZATION;

ANIMALS; ANTIBODIES, VIRAL; BASE SEQUENCE; CELLS, CULTURED; CLONING, MOLECULAR; DNA PRIMERS; GLYCOSYLATION; HIV ENVELOPE PROTEIN GP160; HIV-2; LIKELIHOOD FUNCTIONS; MACACA NEMESTRINA; MEMBRANE GLYCOPROTEINS; MODELS, GENETIC; MOLECULAR SEQUENCE DATA; MONKEY DISEASES; NEUTRALIZATION TESTS; SEQUENCE ANALYSIS, DNA; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; SIMIAN IMMUNODEFICIENCY VIRUS; VIRAL ENVELOPE PROTEINS;

HUMAN IMMUNODEFICIENCY VIRUS 2; MACACA; MACACA NEMESTRINA; SIMIAN IMMUNODEFICIENCY VIRUS;

EID: 23844453184     PISSN: 00472565     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-0684.2005.00123.x     Document Type: Article

References (34)

1. Baba TW, Liska V, Hofmann-Lehmann R, Vlasak J, Xu W, Ayehunie S, Cavacini LA, Posner MR, Katinger H, Stiegler G, Bernacky BJ, Rizvi TA, Schmidt R, Hill LR, Keeling ME, Lu Y, Wright JE, Chou TC, Ruprecht RM: Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian-human immunodeficiency virus infection. Nat Med 6:200-206, 2000.
2. Barbas CF III, Hu D, Dunlop N, Sawyer L, Cababa D, Hendry RM, Nara PL, Burton DR: In vitro evolution of a neutralizing human antibody to human immunodeficiency virus type 1 to enhance affinity and broaden strain cross-reactivity. Proc Natl Acad Sci USA 91:3809-3813, 1994.
3. Bolmstedt A, Sjolander S, Hansen JE, Akerblom L, Hemming A, Hu SL, Morein B, Olofsoon S: Influence of N-linked glycans in V4-V5 region of human immunodeficiency virus type 1 glycoprotein gp160 on induction of a virus-neutralizing humoral response. J Acquir Immune Defic Syndr Hum Retrovirol 12:213-220, 1996.
4. Buckner C, Gines LG, Saunders CJ, Vojtech L, Srivastava I, Gettie A, Bohm R, Blanchard J, Barnett SW, Safrit JT, Stamatos L: Priming B cell-mediated anti-HIV envelope responses by vaccination allows for the long-term control of infection in macaques exposed to a R5-tropic SHIV. Virol 320:167-180, 2004.
5. Burns DPW, Collignon C, Desrosiers RC: Simian immunodeficiency virus mutants resistant to serum neutralization arise during persistent infection of rhesus-monkeys. J Virol 67:4104-4113, 1993.
6. Calef CMJ, O'Connor DH, Watkins DI, Korber BT: Numbering positions in SIV relative to SIVMM239. In: HIV Sequence Compendium. KUIKEN (ed.). Los Alamos, NM: Theoretical Biology and Biophysics Group, Los Alamos National Laboratory 171-181, 2001.
7. Cecilia D, Kleeberger C, Munoz A, Giorgi JV, Zolla-Pazner S: A longitudinal study of neutralizing antibodies and disease progression in HIV-1-infected subjects. J Infect Dis 179:1365-1374, 1999.
8. Chackerian B, Haigwood NL, Overbaugh J: Characterization of a CD4-expressing macaque cell line that can detect virus after a single replication cycle and can be infected by diverse simian immunodeficiency virus isolates. Virology 213:386-394, 1995.
9. Chackerian B, Rudensy LM, Overbaugh J: Specific N-linked and O-linked glycosylation modifications in the envelope V1 domain of simian immunodeficiency virus variants that evolve in the host alter recognition by neutralizing antibodies. J Virol 71:7719-7727, 1997.
10. Cheng-Mayer C, Brown A, Harouse J, Luciw PA, Mayer AJ: Selection for neutralization resistance of the simian human immunodeficiency virus SHIVSF33A variant in vivo by virtue of sequence changes in the extracellular envelope glycoprotein that modify N-linked glycosylation. J Virol 73:5294-5300, 1999.
11. Cole KS, Rowles JL, Jagerski BA, Murphey-Corb M, Unangst T, Clements JE, Robinson J, Wyand MS, Desrosiers RC, Montelaro RC: Evolution of envelope-specific antibody responses in monkeys experimentally infected or immunized with simian immunodeficiency virus and its association with the development of protective immunity. J Virol 71:5069-5079, 1997.
12. Davis D, Stephenss DM, Willers C, Llachmann PJ: Glycosylation governs the binding of antipeptide antibodies to regions of hypervariable amino acid sequence within recombinant gp120 of human immunodeficiency virus type 1. J Gen Virol 71(Pt 12):2889-2898, 1990.
13. Emini EA, Schleif WA, Nunberg JH, Conley AJ, Eda Y, Tokiyoshi S, Putney SD, Matsushita S, Cobb KE, Jett CM, Eichberg JW, Murthy KK: Prevention of HIV-1 infection in chimpanzees by gp120 V3 domain-specific monoclonal antibody. Nature 355:728-730, 1992.
14. Ferrantelli F, Hofmann-Lehmann R, Rasmussen RA, Wang T, Xu W, Li PL, Montefiori DC, Cavacini LA, Katinger H, Steigler G, Anderson DC, McClure HM, Ruprecht RM: Post-exposure prophylaxis with human monoclonal antibodies prevented SHIV89.6P infection or disease in neonatal macaques. AIDS 17:301-309, 2003.
15. Gaudin MC, Safrit JT, Weir R, Fung MS, Koup RA: Pre- and post-exposure protection against human immunodeficiency virus type 1 infection mediated by a monoclonal antibody. J Infect Dis 171:1203-1209, 1995.
16. Haigwood NL, Watson A, Sutton WIT, Mcclure J, Lewis A, Ranchalis J, Travis B, Voss G, Letvin NL, Hu SL, Hirsch VM, Johnson PR: Passive immune globulin therapy in the SIV/macaque model: early intervention can alter disease profile. Immunol Lett 51:107-114, 1996.
17. Hirsch VM, Dapolito G, Hahn A, Lifson J, Montefiori D, Brown CR, Goeken R: Viral genetic evolution in macaques infected with molecularly cloned simian immunodeficiency virus correlates with the extent of persistent viremia. J Virol 72:6482-6489, 1998.
18. Igarashi T, Brown C, Azadegan A, Haigwood N, Dimitrov D, Martin MA, Shibata R: Human immunodeficiency virus type 1 neutralizing antibodies accelerate clearance of cell-free virions from blood plasma. Nat Med 5:211-216, 1999.
19. Kiuken C: Reagents for HIV/SIV vaccine studies. In: HIV Sequence Compendium. Kuiken (ed.). Los Alamos, NM: Theoretical Biology and Biophysics Group, Los Alamos National Laboratory 182-190, 2001.
20. Letvin NL, Robinson S, Rohne D, Axthelm MK, Fanton JW, Bilska M, Palker TJ, Liao HX, Haynes BF, Montefiori DC: Vaccine-elicited V3 loop-specific antibodies in rhesus monkeys and control of a simian-human immunodeficiency virus expressing a primary patient human immunodeficiency virus type 1 isolate envelope. J Virol 75:4165-4175, 2001.
21. Mascola JR: Defining the protective antibody response for HIV-1. Curr Mol Med 3:209-216, 2003.
22. Mascola JR, Stiegler G, Vancott TC, Katinger H, Carpenter CB, Hanson CE, Beary H, Hayes D, Frankel SS, Birx DL, Lewis MG: Protection of macaques against vaginal transmission of a pathogenic HlV-1/SIV chimeric virus by passive infusion of neutralizing antibodies. Nat Med 6:207-210, 2000.
23. Moog C, Fleury HJA, Pellegrin I, Kirn A, Aubertin AM: Autologous and heterologous neutralizing antibody responses following initial seroconversion in human immunodeficiency virus type 1-infected individuals. J Virol 71:3734-3741, 1997.
24. Nishimura Y, Igarashi T, Haigwood N, Sadjadpour R, Plishka RJ, Buckler-White A, Shibata R, Martin MA: Determination of a statistically valid neutralization titer in plasma that confers protection against simian-human immunodeficiency virus challenge following passive transfer of high-titered neutralizing antibodies. J Virol 76:2123-2130, 2002.
25. Nishimura Y, Igarashi T, Haigwood NL, Sadjapour R, Donau OK, Buckler C, Plishka RJ, Buckler-White A, Martin MA: Transfer of neutralizing IgG to macaques 6 h but not 24 h after SHIV infection confers sterilizing protection: implications for HIV-1 vaccine development. Proc Natl Acad Sci USA 100:15131-15136, 2003.
26. Overbaugh J, Rudensey L: Alterations in potential sites for glycosylation predominate during evolution of the simian immunodeficiency virus envelope gene in macaques. J Virol 66:5937-5948, 1992.
27. Parker CE, Deterding LJ, Hager-Braun C, Binley JM, Schulke N, Katinger H, Moore JP, Tomer KB: Fine definition of the epitope on the gp41 glycoprotein of human immunodeficiency virus type 1 for the neutralizing monoclonal antibody 2F5. J Virol 75:10906-10911, 2001.
28. Richman DD, Wrin T, Little SJ, Petropoulos CJ: Rapid evolution of the neutralizing antibody response to HIV type 1 infection. Proc Natl Acad Sci USA 100:4144-4149, 2003.
29. Shibata R, Igarashi T, Haigwood N, Buckler-White A, Ogert R, Ross W, Willey R, Cho MW, Martin MA: Neutralizing antibody directed against the HIV-1 envelope glycoprotein can completely block HIV-1/SIV chimeric virus infections of macaque monkeys. Nat Med 5:204-210, 1999.
30. Trkola A, Pomales AB, Yuan H, Korber B, Maddon PJ, Allaway GP, Katinger H, Barbas CF III, Burton DR, Ho DD, Moore JP: Cross-clade neutralization of primary isolates of human immunodeficiency virus type 1 by human monoclonal antibodies and tetrameric CD4-IgG. J Virol 69:6609-6617, 1995.
31. Wei X, Decker JM, Wang S, Hui H, Kappes JC, Wu X, Salazar-Gonzalez JF, Salazar MG, Kilby JM, Saag MS, Komarova NL, Nowak MA, Hahn BH, Kwong PD, Shaw GM: Antibody neutralization and escape by HIV-1. Nature 422:307-312, 2003.
32. Wolinsky SM, Wike CM, Korber BT, Hutto C, Parks WP, Rosenblum LL, Kuntsman KJ, Furtado MR, Munoz JL: Selective transmission of human immunodeficiency virus type-1 variants from mothers to infants. Science 255:1134-1137, 1992.
33. Wyatt R, Kwong PD, Desjardins E, Sweet RW, Robinson J, Hendrickson WA, Sodroski JG: The antigenic structure of the HIV gp120 envelope glycoprotein. Nature 393:705-711, 1998.
34. Wyatt R, Sodroski J: The HIV-1 envelope glycoproteins: fusogens, antigens, and immunogens. Science 280:1884-1888, 1998.